complete response


Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia.

complete response (CR)

(in oncology) the total disappearance of a tumor.

complete response

Abbreviation: CR
In cancer care, the eradication by treatment of all of a readily identifiable tumor. A complete response differs from a cure in that microscopic amounts of tumor the may remain in the patient and later produce a relapse.
See also: response
References in periodicals archive ?
In the February Complete Response Letter, the FDA acknowledged objective and subjective efficacy at the beginning and end of treatment in elderly patients, and at the beginning of treatment for non-elderly adult patients, and the most recent Complete Response Letter did not alter those conclusions," continued Pascoe.
In its Complete Response letter, FDA asserts that the BEST clinical study, which serves as the pivotal Phase III trial for the application, does not adequately demonstrate efficacy of Gencaro in reducing all-cause mortality in patients with heart failure.
The primary endpoint of the trial was complete response rate, which was determined by CT scan, the conventional methodology, and PET scan.
A Complete Response Letter informs companies that an application is not ready for approval.
This complete response letter has been issued by the US Food and Drug Administration (FDA).
M2 EQUITYBITES-January 22, 2013-Impax Pharmaceuticals gets FDA's complete response letter for RYTARY's NDA(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-April 27, 2012-US FDA issues Complete Response Letter to Amgen for XGEVA(C)2012 M2 COMMUNICATIONS
The objective response rate (ORR) was 73 percent, including a 34 percent complete response (CR) rate, 1 percent partial response (PR) rate, 24 percent marrow CR rate with or without other hematologic improvement (HI) responses, and a 14 percent HI rate.
M2 EQUITYBITES-September 10, 2012-Janssen Research & Development LLC submits complete response for XARELTO(C)2012 M2 COMMUNICATIONS http://www.
M2 PHARMA-September 6, 2011-Discovery Labs submits Complete Response to FDA for SURFAXIN(C)2011 M2 COMMUNICATIONS
One complete response, confirmed to be PET-negative, was deemed by the independent radiologists' assessments to be qualified because the index lesion was in an area that had received prior radiation (a technical protocol violation).
M2 EQUITYBITES-August 2, 2012-Hemispherx Biopharma Inc submits complete response with the FDA for Ampligen's NDA for Chronic Fatigue Syndrome(C)2012 M2 COMMUNICATIONS http://www.

Full browser ?